PharmaDrug Inc. Announces Plans for First-In-Human Clinical Study with PD-001 in Esophageal Cancer
PharmaDrug Inc. plans to conduct a first-in-human study of its lead candidate, PD-001, an enteric-coated cepharanthine-2HCL, in Australia in H2 2023. PD-001 has the potential as a breakthrough therapy ...
Jubilant Therapeutics’ JBI-778 Granted Orphan Drug Designation by US FDA for Glioblastoma Multiforme Treatment
Jubilant Therapeutics, a clinical-stage biopharmaceutical company, has announced that JBI-778, an oral PRMT5 inhibitor, has received orphan drug designation from the U.S. Food and Drug Administration ...
IASO Bio’s CT103A Receives RMAT & Fast Track Designation from FDA for Treating Relapsed/Refractory Multiple Myeloma
IASO Biotherapeutics, a clinical-stage biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has granted both Regenerative Medicine Advanced Therapy (RMA ...